17.11.2005 14:37:00
|
Smith & Nephew Endoscopy Appoints Executives to Lead Research and Development and Marketing Efforts
ANDOVER, Mass., Nov. 17 /PRNewswire/ -- Smith & Nephew's Endoscopy division today announced the appointments of Sally L. Maher as Vice President, Research and Development, and Joseph G. Darling as Vice President of Marketing.
Sally Maher
Maher, who has more than 15 years of experience in the medical device, pharmaceutical and biotechnology industries, had served as Smith & Nephew Endoscopy's Vice President of Government Affairs. She joined Smith & Nephew in 1999 and managed the transition team after Endoscopy acquired Orthopaedic Biosystems Ltd. (OBL) in 2001.
Maher holds a bachelor's degree from the Ohio Wesleyan University in Delaware, Ohio, and a law degree from the University of Baltimore in Maryland.
"Our R&D efforts are critical to the long-term success of this organization," said Jim Taylor, President, Endoscopy. "Sally's keen understanding of business, industry and clinical needs has added greater scope to our organization."
Joseph G. Darling
As Vice President of Marketing, Darling will be responsible for Endoscopy's worldwide strategic marketing direction. He brings to Smith & Nephew Endoscopy more than 20 years of experience in the medical industry, most recently at Baxter International where he served as Vice President of Marketing, U.S. Medication Delivery Systems. He also held executive and leadership positions at Wyeth-Ayerst Pharmaceuticals and Abbott Laboratories.
"Joe's professional experience in both marketing and sales has provided him with an in-depth understanding of the healthcare industry's most complex issues, including healthcare economics and reimbursement," Taylor said. "We look forward to his contributions to the Endoscopy organization."
Darling is a graduate of Syracuse University in Syracuse, N.Y. About Smith & Nephew
Smith & Nephew (http://www.smith-nephew.com/) is a global medical technology business, specializing in Endoscopy, Orthopaedics and Advanced Wound Management products. Smith & Nephew ranks as the global leader in arthroscopy and one of the world's leaders in advanced wound management and is one of the fastest growing orthopaedics companies in the world.
Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeon and professional healthcare customers, with whom its name is synonymous with the highest standards of performance, innovation and trust. The company has more than 8,000 employees and operates in 33 countries around the world and generated sales of nearly $2.3 billion.
Forward Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. In particular, statements regarding expected revenue growth and operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation, claims and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward- looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.
All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Contact: Joe Metzger Smith & Nephew Endoscopy (978) 749-1330
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Smith & Nephew plcmehr Nachrichten
26.11.24 |
FTSE 100-Titel Smith Nephew-Aktie: So viel Verlust hätte eine Investition in Smith Nephew von vor 3 Jahren bedeutet (finanzen.at) | |
19.11.24 |
FTSE 100-Wert Smith Nephew-Aktie: So viel Verlust hätte ein Investment in Smith Nephew von vor einem Jahr eingebracht (finanzen.at) | |
19.11.24 |
LSE-Handel: FTSE 100 klettert zum Handelsstart (finanzen.at) | |
12.11.24 |
Dienstagshandel in London: FTSE 100 schlussendlich schwächer (finanzen.at) | |
12.11.24 |
Börse London: FTSE 100 verliert am Dienstagnachmittag (finanzen.at) | |
12.11.24 |
Anleger in London halten sich zurück: FTSE 100 in der Verlustzone (finanzen.at) | |
12.11.24 |
FTSE 100-Papier Smith Nephew-Aktie: So viel Verlust hätte ein Investment in Smith Nephew von vor 10 Jahren bedeutet (finanzen.at) | |
12.11.24 |
Anleger in London halten sich zurück: FTSE 100 fällt zum Start (finanzen.at) |
Analysen zu Smith & Nephew plcmehr Analysen
Aktien in diesem Artikel
Smith & Nephew plc | 11,74 | 0,73% |
Indizes in diesem Artikel
FTSE 100 | 8 275,09 | 0,00% | |
FTSE Allshare | 4 517,87 | 0,08% |